Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine in Japanese Patients with TRD
NCT02918318Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esketamine in treatment-resistant depression (TRD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Rating Scale Total Score at Day 28. Started Dec 2016; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02918318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918318.